AvalonRx, Avalon’s proprietary drug discovery platform, was used to screen, identify and characterize compounds from Novartis’s proprietary compound library. Avalon said that candidate hit compounds were successfully identified by monitoring gene expression changes of a transcriptional signature reflecting disruption of the selected pathway.
The parties have agreed to initiate characterization of the identified compounds which triggers an undisclosed payment to Avalon for research support under the terms of the agreement.